Sylvia Wang

As a senior scientist in the Cancer Pharmacology team, Sylvia Wang leads the in vivo immuno-oncology (I/O) platform for internal studies. She is primarily responsible for establishing new I/O models using human immune system reconstitution mice and TAA (tumor-associated antigen) targets using humanized mice models. She has approximately five years of experience in biological drug development and holds a PhD in tumor pathology from Nagoya University in Japan. Before joining Crown Bioscience, Sylvia Wang was a postdoctoral researcher at the College of Pharmaceutical Sciences, Zhejiang University, where she focused on novel drug development.